Innovation systems in a finance dominated accumulation regime - Results and theses;Innovationssysteme in einem finanzdominierten Akkumulationsregime - Befunde und Thesen

Geographische Zeitschrift

Volumn 91, Issue 3-4, 2003, Pages 133-155

  Zeller, Christian ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY; FINANCIAL PROVISION; INNOVATION; INVESTMENT; RESEARCH AND DEVELOPMENT;

NORTH AMERICA; UNITED STATES; WESTERN HEMISPHERE; WORLD;

EID: 13244255404     PISSN: 00167479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (78)

1. AAAS (2004a): AAAS Report XXIX Research and Development FY 2005: American Association for the Advancement of Science, Washington, DC. gesichtet: 30 March 2004. http://www.aaas.org/spp/rd/05pch3.pdf
2. AAAS (2004b): Guide to R&D Funding Data - Historical Trends in Federal R&D: American Association for the Advancement of Science, Washington, DC. gesichtet: 4 May 2004. http://www.aaas.org/spp/ rd/guihist.htm
3. AAAS (2004c): Bush Proposes to Cut Nondefense R&D Over the Next Five Years to Reduce Deficit. 22 April 2004, gesichtet: 4 May 2004. http://www.aaas.org/spp/rd/proj05p.htm
4. Aglietta, M. (2000): Shareholder value and corporate governance: some tricky questions, Economy and Society 29 (1), S. 146-159.
5. Argyres, N. S. and Liebeskind, J. P. (1998): Privatizing the intellectual commons: Universities and the commercialization of biotechnology, Journal of Economic Behavior & Organization 35 (4), S. 427-454.
6. Bagchi-Sen, S., Smith, H. L. and Hall, L. (2004): The US biotechnology industry: industry dynamics and policy, Environment & Planning C: Government and Policy 22 (2), S. 199-216.
7. Baygan, G. and Freudenberg, M. (2000): The Internationalisation of Venture Capital Activity in OECD Countries: Implications for Measurement and Policy 19 December, OECD: Paris
8. Boyer, R. (1988): Technical change and the theory of ,Régulation'. G. Dosi/C. Freeman/R. Nelson/G. Silverberg/L. Soete (Hg.): Technical Change and Economic Theory. London, S. 67-94.
9. Boyer, R. (1992): Les alternatives au fordisme. Des années 1980 au XXIe siècle. G. "Benko/A. Lipietz (Hg.): Les régions qui gagnent. Paris, S. 189-223.
10. Boyer, R. (2000): Is a finance-led growth regime a viable alternative to Fordism? A preliminary analysis, Economy and Society 29 (1), S. 111-145.
11. Boyer, R. and Saillard, Y. (2002): Un précis de la régulation. R. Boyer/Y. Saillard (Hg.): Théorie de la régulation. Paris, S. 58-68.
12. Brenner, R. (2002): The Boom and the Bubble: The US in the World Economy. London, New York.
13. Burrill & Co (1998): 1998 Quarterly Press Releases: First Quarter 1998: Burrill & Co. April l, 1998, gesichtet: 24 November 2000. http://www.burrillandco.com/content_pr.html
14. Burrill & Co (1999): 1999 Quarterly Press Release: Fourth Quarter 1999. 1999 ends on a positive note for biotechnology: Burrill & Co. January 4, 2000, gesichtet: 24 November 2000. http://www.burrillandco.com/content_pr_99g4.html
15. Burrill & Co (2000): Second Quarter 2000: Another busy quarter for biotech as the second quarter 2000 ends on a high note: Burrill & Co.: 2000 Quarterly Press Releases. 3 July 2000, gesichtet: November 24, 2000. http://www.burrillandco.com/content_pr_00g2.html
16. Burrill & Co (2001): First Quarter 2001: Biotech Financing Window Closes Amid a Market Downturn. Sequencing the Human Genome Not Enough: Burrill & Co.: 2001 Quarterly Press Releases. 2 April 2001, gesichtet: 25 July 2001. http://www.burrillandco.com/ content_pr_01g1.html
17. Burrill & Co (2002): Second Quarter 2002: Biotech continues its downward spiral during Q2 02. Wall Street's enthusiasm wanes as Investors wait for a turn around ... Burrill & Co.: 2002 Quarterly Press Releases. 1 July 2002, gesichtet: July 25, 2002. http://www.burrillandco.com/content_pr_02g2.html
18. Burrill & Co (2003): Second Quarter 2003: Biotech Ends Q2 03 on strong ground. Total financing doubled from 1Q 03 to 2Q 02, reaching $3.8 billion: Burrill & Co.: 2003 Quarterly Press Releases. 7 July 2003, gesichtet: September 26, 2003. http:// www.burrillandco.com/content_pr_03q2.html
19. Burrill & Co (2004): First Quarter 2004: Biotech Posts Its Best 1Q in Four Years: Burrill & Co.: 2003 Quarterly Press Releases. 1 April 2004, gesichtet: April 19, 2004. http://www.burrillandco.com/ content_pr_03q2.html
20. BVK (2003a): BVK Nachrichten 2. Juli 2003, BVK Bundesverband deutscher Kapitalbeteiligungsgesellschaften, Redaktion Holger Frommann: Berlin, 31 p
21. BVK (2003b): BVK Nachrichten 25. Juli 2003, BVK Bundesverband deutscher Kapitalbeteiligungsgesellschaften, Redaktion Holger Frommann: Berlin, 14 p
22. Caves, R. E. (1996): Multinational enterprise and economic analysis (Second Editin). Cambridge.
23. Chesnais, F. (1997): La mondialisation du capital (nouvelle Edition augmentée). Paris.
24. Chesnais, F. (2003): Rapports de propriété et formes de captation du "cognitif" au bénéfice du capitalisme financier. C. Vercellone (Hg.): Sommes nous sortis du capitalisme industriel? Paris, S. 167-179.
25. Chesnais, F. (2004a): Das finanzdominierte Akkumumulationsregime: theoretische Begründung und Reichweite. C. Zeller (Hg.): Die globale Enteignungsökonomie. Münster, S. 217-254.
26. Chesnais, F. (2004b): Le capital de placement: accumulation, internationalisation, effets économiques et politiques. F. Chesnais (Hg.): La finance mondialisé. Paris, S. 15-50.
27. Chesnais, F./Sauviat, C. (2000): The financing of innovation-related investment in the contemporary global finance-led accumulation regime. Research Project on Local Productive Systems and New Industrial and Technological Policies'. Rio de Janeiro, S. 25-73.
28. Chesnais, F. and Serfati, C. (2000): La gestion de l'innovation dans le regime d'accumulation à dominante financiére. M. Delapierre/P. Moati/E. M. Mouhoud (Hg.): Connaissance et Mondialisation. Paris, S. 183-193.
29. Cohen, W., Nelson, R. and Walsh, J. P. (2000): Protecting their intellectual assets: Appropriability conditions and why U.S. manufacturing firms patent (or not), National Bureau of Economic Research: Cambridge, MA, 50 p.
30. Cooke, P. (2001): New Economy Innovation Systems: Biotechnology in Europe and the USA, Industry and Innovation 8 (3), S. 267-289.
31. Cooke, P. (2004): The molecular biology revolution and the rise of bioscience megacentres in North America and Europe, Environment and Planning C: Government and Policy 22 (2), S. 161-177.
32. Coriat, B. and Orsi, F. (2002): Establishing a new intellectual property rights regime in the United States: Origins, content and problems, Research Policy 31 (8-9), S. 1491-1507.
33. Cortright, J. and Mayer, H. (2002): Signs of Life: The Growth of Biotechnology in the U.S., The Brookings Institution: Washington DC, 44 p
34. Dasgupta, P. and David, P. A. (1994); Toward a new economics of science, Research Policy 23 (5), S. 487-521.
35. Delapierre, M. (1997): Vers l'emergence d'oligopoles en réseau fondés sur la connaissance, Innovations. Cahiers d'économie de l'innovation 5 (1997-1), S. 93-103.
36. Delapierre, M. (2000): Vers l'emergence de nouvelle formes d'oligopoles fondes sur la connaissance. M. Delapierre, P. Moati and E. M. Mouhoud (Hg.): Connaissance et Mondialisation. Paris, S. 97-107.
37. Duménil, G. and Lévy, D. (2004): Le néolibéralis-me sons hégémonie états-unienne. F. Chesnais (Hg.): La finance mondialisé. Paris, S. 71-98.
38. Ernst & Young (Hrsg.) (1998): New directions 98: The Twelth Biotechnolgy Industry Annual Report. Palo Alto, CA.: Ernst & Young LLP, 50 S.
39. Ernst & Young (Hrsg.) (1999): Bridging the Gap 1999: Ernst & Young's 13th Biotechnolgy Industry Annual Report. Palo Alto, CA.: Ernst & Young LLP, 76 S.
40. Ernst & Young (Hrsg.) (2000): Convergence: The Biotechnology Industry Report. Millenium Edition. Palo Alto, CA.: Ernst & Young LLP, 86 S.
41. Ernst & Young (Hrsg.) (2001): Focus on Fundamentals. The Biotechnology Report. 15th Review. Palo Alto, CA.: Ernst & Young LLP, 107 S.
42. Ernst & Young (Hrsg.) (2002): Beyong Borders. The Global Biotechnology Report 2002. UK: Ernst & Young LLP, 86 S.
43. Ernst & Young (Hrsg.) (2003): Resilience. Americas Biotechnology Report 2003. Palo Alto, CA.: Ernst & Young LLP, 44 S.
44. Etzkowitz, H. and Leydesdorff, L. (2000): The dynamics of innovation: from National Systems and "Mode 2" to a Triple Helix of university-industry-government relations, Research Policy 29 (2), S. 109-123.
45. Florida, R. and Kenney, M. (1988): Venture capital-financed innovation and technological change in the USA, Research Policy 17, S. 119-137.
46. Florida, R. and Samber, M. (1999): Capital and Creative Destruction: Venture Capital, Technological Change, and Economic Development. M. Gertler/T. Barnes (Hg.): The New Industrial Geography: Regions, Regulations and Institutions. London, New York, S. 265-291.
47. Florida, R./Smith, D., Jr. (1990): Venture Capital, Innovation, and Economic Development, Economic Development Quarterly 4 (4), S. 345-360.
48. Foray, D. (2002): Intellectual Property and Innovation in the Knowledge-Based Economy, isuma Canadien Journal of Policy Research 3 (1), S. 71-78.
49. Freeman, C. (1995): The ,National System of Innovation in historical perspective, Cambridge Journal of Economics 19 (1), S. 5-24.
50. Gray, M. and Parker, E. (1998): Industrial change and regional development: the case of the US biotechnology and pharmaceutical industries, Environment and Planning A 30 (10), S. 1757-1774.
51. Guellec, D. and Ionnadis, E. (1997): Causes of fluctuations in R&D expenditures: a quantitative analysis, OECD Economic Review (29/II), S. 123-138.
52. Haemmig, M. (2003): The Globalization of Venture Capital. A Management Study of International Venture Capital Firms. Bern, Stuttgart.
53. Heller, M. A. and Eisenberg, R. S. (1998): Can Patents Deter Innovation? The Anticommons in Biomedical Research, Science 280 (5364), S. 698-701.
54. Howells, J. (1999): Regional systems of innovation. D. Archibugi, J. Howells and J. Michie (Hg.): Innovation Policy in a Global Economy. Cambridge, S. 67-93.
55. Huffschmid, J. (2002): Politische Ökonomie der Finanzmärkte (aktualisierte and erweiterte Neuauflage). Hamburg.
56. Husson, M. (2004): Der Kapitalismus nach der "neuen Ökonomie". C. Zeller (Hg.): Die globale Enteignungsökonomie. Münster, S. 127-159.
57. IMP (2003): Global Financial Stability Report. Market Developments and Issues, September 2003. Washington, DC.
58. Kenney, M. (2000): Note on "Venture Capital", Berkeley Roundtable the International Economy: Berkeley, 10 p. http://brie.berkeley.edu/~briewww/pubs/pubs/wp/wp142.pdf
59. Kogut, B. (2000): The Transatlantic Exchange of Ideas and Practices: National Institutions and Diffusion, L'Institut français des relations internationales (Ifri): Paris, 52 p
60. Lazonick, W. and O'Sullivan, M. (2000): Maximizing shareholder value: a new ideology for corporate governance, Economy and Society 29 (1), S. 13-35.
61. Lundvall, B.-Å. (1992): Introduction. B.-Å. Lundvall (Hg.): National systems of innovation: towards a theory of innovation and interactive learning. London.
62. Lütz, S. (2002): Der Staat and die Globalisierung von Finanzmärkten. Regulative Politik in Deutschland, Groß britannien and den USA. Frankfurt/Main.
63. Martin, R., Sunley, P. and Turner, D. (2002): Taking risks in regions: the geographical anatomy of Europe's emerging venture capital market, Journal of Economic Geography 2 (2), S. 121-150.
64. Mayer, C. (2002): Financing the New Economy: financial institutions and corporate governance, Information Economics and Policy 14 (2), S. 311-326.
65. Nelson, R. R. (2004): The market economy, and the scientific commons, Research Policy 33 (3), S. 455-471.
66. OECD (2004): OECD Statistics on Institutional Investors - Data from 1980 Onwards (Data are extracted from the OECD Institutional Investors Database / Institutional Investors - Statistical Yearbook, 1992-2001, 2003 Edition): OECD, Paris. gesichtet: 22. September. http:// www.oocd.org/document/45/0,2340,en_2649_34247_25821741_1_1_1_1,00.html
67. O'Sullivan, M. (2000): The innovative enterprise and corporate governance, Cambridge Journal of Economics 24 (4), S. 393-417.
68. Powell, W., W., Koput, K., W., Bowie, J. I. and Smith-Doerrs, L. (2002): The Spatial Clustering of Science and Capital: Accounting for Biotech Firm-Venture Capital Relationships, Regional Studies 36 (3), S. 291-305.
69. Prevezer, M. (1998): Clustering in Biotechnology in the USA. P. G. M. Swann, M. Prevezer and D. Stout (Hg.): The Dynamics of Industrial Clustering. International Comparisons in Computing and Biotechnology. Oxford, New York, S. 124-193.
70. Prevezer, M. (2001): Ingredients in the Early Development of the U.S. Biotechnology Industry, Small Business Economics 17 (1-2), S. 17-29.
71. Sablowski, T. and Rupp, J. (2001): Die neue Ökonomie des Shareholder Value. Corporate Governance im Wandel, PROKLA. Zeitschrift für kritische Sozialwissenschaft 31 (1/H 122), S. 47-78.
72. Sauviat, C. (2004): Les fonds de pension et les fonds mutuel: acteurs majeurs de la finance mondialisée et du nouveau pouvoir actionnarial. F. Chesnais (Hg.): La finance mondialisé. Paris, S. 99-124.
73. Senker, J. (1996): National systems of innovation, organizational learning and industrial biotechnology*1, Technovation 16 (5), S. 219-229.
74. Serfati, C. (2003): La logique du capital financier au coeur des rapport: de production contemporains. C. Vercellone (Hg.): Sommes nous sortis du capitalisme industriel? Paris, S. 181-206.
75. The Economist (2000): Money to bum., Economist, 355 (8172), May 27: S. 71.
76. Zeller, C. (2002): Project Teams as Means for Restructuring Research and Development in the Pharmaceutical Industry, Regional Studies 36 (3), S. 283-297.
77. Zeller, C. (2004): North Atlantic innovative relations of Swiss pharmaceuticals and the importance of regional biotech arenas, Economic Geography 80 (1), S. 83-111.
78. Zider, B. (1998): How Venture Capital Works, Harvard Business Review. Harvard Business School Publication Corp. Business Review. Harvard Business School Publication Corp.